Enquirer Consulting GroupA short read before our call on Monday, October 5: what we heard, where we would start, and how we work.
Patients enter their symptoms on a tablet questionnaire. Machine learning suggests the clinical lab tests that fit, including more specialized ones, and helps the provider order and interpret them.
The product is ready. The first customers come next.
Doctors, clinical labs, LIMS providers and infectious disease specialists.
To fund marketing and a sales pipeline.
If we have any of this wrong, that is the first thing we would like to hear on Monday.
Doctors, labs, LIMS providers and specialists each buy for a different reason, through a different person, on a different timeline. Going after all four at launch splits a small team four ways.
A practice owner, a lab director and a LIMS product lead care about different things. The same pitch to all of them lands with none of them.
First conversations with buyers have to be opened on purpose, week after week. There is no system yet that opens them.
This is our read from one conversation. Tell us where we have it wrong.
Our starting read, to test with you on Monday. Choosing the first buyer is the first decision of the build.
| Buyer | Why they might buy | Who usually decides | What they will ask first |
|---|---|---|---|
| Doctors and their practices | Better-matched test orders, starting from a structured symptom intake | The practice owner or medical director, with the practice manager on workflow | How it fits the visit, who signs off on each suggestion, and how patient data is handled |
| Clinical labs | More appropriate orders, including the specialized tests the lab runs | The lab director, or the lab's outreach and business development lead | Which tests it suggests, and how orders reach the lab |
| LIMS providers | A decision support feature to offer their lab customers | The partnerships or product lead | How much integration work it takes, and who supports it |
| Infectious disease specialists | Symptom-led test selection, where the right test may be a specialized one | The specialist, or the lead physician of the group | The clinical evidence behind the suggestions |
One buyer where a yes can come quickly and repeat, and one that can bring volume later. A practice can say yes quickly, for one practice. A lab or a LIMS provider takes longer, and can bring many users at once. We would set the order with you.
Whether the app needs regulatory clearance, and which patient data rules apply, are questions for your regulatory and legal advisers. We build the outreach around the answers. We do not give regulatory advice.
We help you choose the first buyer, then build a named list of the people who decide, by role and region, checked before anyone is contacted.
A message for each type of buyer, in plain clinical language, built on what the app does and the proof you have today.
Steady email and LinkedIn outreach to those people, from mailboxes and profiles set up for the purpose. Every reply answered fast, and every interested buyer booked onto a call with you.
Website and search, PR, video and social. They matter once there are customers to talk about. Before launch, the work that counts is reaching the first buyers.
Investors ask what buyers say. Before launch, the strongest answer is a real one: named practices and labs in conversation, and a pipeline you can show week by week.
That is what the engine is built to produce. It opens the conversations and books them with you. The conversations, and the relationships, stay yours.
We make no promise on results before it runs. The four months show what it does for Novabiota.
We choose the first buyer with you, build the list and the messages, and set up the sending and the CRM.
We run it live, report every week, and tune it on what buyers tell us. First conversations land early, not at the end.
We teach the person you pick to run it, then hand over the playbook, the dashboards and the system. You can run it without us.
If you would rather we keep running it, there is an optional managed service.
What we need from you: a few hours in the first two weeks for input on your buyers and your offer, sign-off on the messages, and a named person for replies to go to.
You get one point of contact for all of it.
Cumulative figures across live campaigns and client features, pulled from the live platforms on July 10, 2026. New business is client-reported. A qualified conversation is a positive or interested reply. Results vary by market and offer. They show what we have achieved for others, not a promise of your result.
Sells to US clinicians and the administrators around them, people with very little time for a sales rep. We built prospecting and personalized outreach across cold email and LinkedIn.
“Enquirer Consulting Group provided the tools to allow us to personalize outreach at scale in a way that simply wasn't possible before.”
What they report: prospecting and research automated, and the team freed to focus on relationships and closing.
Disclosure: Innovative Medical's Sales Director also works with Enquirer Consulting Group as a consultant on US medical sales.
Parts, service and equipment for the imaging systems in US hospitals and clinics. We built and ran a full outbound channel across cold email and LinkedIn.
“ECG and Enquirer AI helps us identify the right people and start the conversation in a much smarter way.”
What they report: a record growth year, with outreach modernized from cold calling to targeted, data-led conversations.
Neither sells clinical software, and results vary by market. Both case studies, with video: enquirerconsulting.com/case-studies